Anaïs Vallet‐Pichard

Cystic fibrosis liver disease progression in the era of elexacaftor–tezacaftor–ivacaftor Open

Charlotte Mouliade, Lucia Parlati, Stylianos Tzedakis, Mathis Collier, Samir Bouam , et al. · 2025

In this nationwide French cohort study of over 10,000 people with cystic fibrosis, we observed a significant decline in the incidence of cystic fibrosis liver disease outcomes following the rollout of elexacaftor-tezacaftor-ivacaftor (ETI)…

ACBP/DBI neutralization for the experimental treatment of fatty liver disease Open

Omar Motiño, Flavia Lambertucci, Adrien Joseph, Sylvère Durand, Gerasimos Anagnostopoulos , et al. · 2024

Acyl-CoA binding protein (ACBP), also known as diazepam-binding inhibitor (DBI), is an extracellular checkpoint of autophagy. Here, we report that patients with histologically confirmed metabolic-associated steatohepatitis (MASH) or liver …

Factors associated with high costs of patients with metabolic dysfunction-associated steatotic liver disease: an observational study using the French CONSTANCES cohort Open

Arnaud Nze Ossima, Angélique Brzustowski, Valérie Paradis, Bernard E. Van Beers, Catherine Postic , et al. · 2024

Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort) Open

Patrizia Carrieri, Marc Bourlière, Vincent Di Beo, Clovis Lusivika‐Nzinga, Clémence Ramier , et al. · 2023

Histological Characteristics and Management of Hepatitis on Immune Checkpoint Inhibitors: A Retrospective Descriptive Study Open

Lucia Parlati, Kennie Marcin, Benoît Terris, Anaïs Vallet‐Pichard, Marion Corouge , et al. · 2023

Background and aims: the side effects of immune checkpoint inhibitors (ICI) pose a problem for the clinical management of cancer patients. There is a lack of knowledge of the value of liver biopsy in patients with ICI-related drug-induced …

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter prospective st…

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis (AF) remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter, prospective study assessed …

High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold Open

Laurent Castéra, Cédric Laouénan, Anaïs Vallet‐Pichard, Tiphaine Vidal-Trécan, Pauline Manchon , et al. · 2023

OBJECTIVE Most people with type 2 diabetes (T2DM) and nonalcoholic steatohepatitis (NASH) or advanced fibrosis remain undiagnosed, resulting in missed opportunities for early intervention. This multicenter prospective st…

Patients Treated for HCV Infection and Listed for Liver Transplantation in a French Multicenter Study: What Happens at Five Years? Open

Lucy Meunier, Mohamed Belkacemi, George Philippe Pageaux, Sylvie Radenne, Anaïs Vallet‐Pichard , et al. · 2022

Background: Direct-acting antiviral (DAA) agents for the treatment of hepatitis C virus (HCV) infection have been proven safe and effective in cirrhotic patients awaiting liver transplantation (LT). However, in the long term, data remain m…

Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort Open

Tangui Barré, Fabrice Carrat, Clémence Ramier, Hélène Fontaine, Vincent Di Beo , et al. · 2022

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis Open

Georges‐Philippe Pageaux, Clovis Lusivika‐Nzinga, Nathalie Ganne‐Carrié, Didier Samuel, Céline Dorival , et al. · 2022

Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis Open

Pierre Nahon, Marie Najean, Richard Layese, Kevin Zarca, Laeticia Blampain Segar , et al. · 2021

Cannabis Use Is Inversely Associated with Overweight and Obesity in Hepatitis B Virus-Infected Patients (ANRS CO22 Hepather Cohort) Open

Tangui Barré, Stanislas Pol, Clémence Ramier, Vincent Di Beo, Fabrice Carrat , et al. · 2021

Background: Chronic hepatitis B virus (HBV) infection may evolve into cirrhosis and hepatocellular carcinoma, and this progression may be accelerated by specific risk factors, including overweight and obesity. Although evidence for …

Prospective external validation of a new non‐invasive test for the diagnosis of non‐alcoholic steatohepatitis in patients with type 2 diabetes Open

Thierry Poynard, Valérie Paradis, Jimmy Mullaert, Olivier Deckmyn, Nathalie Gault , et al. · 2021

Summary Background One of the unmet needs in patients with type 2 diabetes mellitus (T2DM) is the prediction of non‐alcoholic liver disease by non‐invasive blood tests, for each of the three main histological features, fibrosis, non‐alcoho…

Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered” Open

Vincent Mallet, Vincent Mallet, K Böck, Mourad Dellagi, Marion Tano , et al. · 2021

Is elimination of HCV realistic by 2030: France Open

Stanislas Pol, Loriane Lair‐Mehiri, Anaïs Vallet‐Pichard · 2021

The World Health Organization (WHO) has proposed a plan for the elimination of viral hepatitis with a goal of reducing new hepatitis infections by 30% and 90% in 2020 and 2030, and associated mortality by 10% and 65% respectively. Actions …

Intravenous ketamine and progressive cholangiopathy in COVID-19 patients Open

Vincent Mallet, K Böck, Paul Doumbe Mandengue, Nicolas Dufour, Torsten Voigtlaender , et al. · 2021

Outcome of SARS-CoV-2 infection is linked to MAIT cell activation and cytotoxicity Open

Héloïse Flament, Matthieu Rouland, Lucie Beaudoin, Amine Toubal, Léo Bertrand , et al. · 2021

Immune system dysfunction is paramount in coronavirus disease 2019 (COVID-19) severity and fatality rate. Mucosal-associated invariant T (MAIT) cells are innate-like T cells involved in mucosal immunity and protection against viral infecti…

Outcome of SARS-CoV-2 infection linked to MAIT cell activation and cytotoxicity: evidence for an IL-18 dependent mechanism Open

Héloïse Flament, Matthieu Rouland, Lucie Beaudoin, Amine Toubal, Léo Bertrand , et al. · 2020

Immune system dysfunction is paramount in Coronavirus disease 2019 (COVID-19) severity and fatality rate. Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells involved in mucosal immunity and protection against viral infecti…

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort Open

Anaïs Vallet‐Pichard, Jean-Michel Corréas, Céline Dorival, Fabien Zoulim, Albert Tran , et al. · 2020

Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report Open

Estelle Charvet, C. Lheure, C. Isnard, Nicolás Franck, N. Kramkimel , et al. · 2020

L’index FIB-4 pour faire le diagnostic de fibrose hépatique avancée au cours de la stéatose hépatique Open

Vincent Mallet, Lucia Parlati, Anaïs Vallet‐Pichard, Benoît Terris, Emmanuel Tsochatzis , et al. · 2019

Direct‐acting antivirals and the risk of hepatocellular carcinoma: The end of a polemic? Open

Stanislas Pol, Anaïs Vallet‐Pichard, Hélène Fontaine, Fabrice Carrat · 2019

See Article on Page 448

Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective Open

Laurent Alric, Isabelle Ollivier‐Hourmand, Emilie Bérard, Sophie Hillaire, Maéva Guillaume , et al. · 2018

Mortality associated with the treatment of HCV with direct-acting antivirals Open

Anne Laurain, Laura D. Kramer, Philippe Sultanik, Anaïs Vallet‐Pichard, Philippe Sogni , et al. · 2017

We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have…

Grazoprevir/elbasvir combination therapy for HCV infection Open

Anaïs Vallet‐Pichard, Stanislas Pol · 2016

Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or pari…

Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure Open

Jérôme Dumortier, François Bailly, Georges‐Philippe Pageaux, Anaïs Vallet‐Pichard, Sylvie Radenne , et al. · 2016

Background Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in t…

The relationship between liver stiffness measurement and outcome in patients with chronic hepatitis C and cirrhosis: a retrospective longitudinal hospital study Open

Philippe Sultanik, Ludwig Kramer, Damien Soudan, Samir Bouam, Jean–François Méritet , et al. · 2016

Summary Background There is a relationship between liver stiffness measurement ( LSM ) and outcome of HCV patients. Aim To evaluate the performance of LSM to predict outcome of HCV patients at risk of liver‐related complication. Methods We…

An update on the management of hepatitis C virus-infected patients with stage 4–5 chronic kidney disease while awaiting the revised KDIGO Guidelines Open

Stanislas Pol, Michel Jadoul, Anaïs Vallet‐Pichard · 2016

The treatment of hepatitis C virus (HCV) infection has progressed markedly over the last 2 decades, with a dramatic acceleration the last 3 years. The combination of two or three direct-acting antiviral drugs (DAAs) targeting viral protein…

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life Open

Stanislas Pol, Anaïs Vallet‐Pichard, Marion Corouge · 2016

The treatment of hepatitis C virus has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals and agents with non-viral targets (cyclophilin inhibitors, interferon-lambda, vaccine th…

Anaïs Vallet‐Pichard YOU? Author Swipe